Core Insights - VolitionRx Limited is focusing on commercializing its Nu.Q® platform in the human diagnostics market, with ongoing discussions with over ten companies, whose combined market value exceeds $600 billion [2] - The company aims to secure multiple licensing agreements in the human diagnostics space this year, similar to its strategy in the veterinary market [3] - Volition recorded its first revenue from sales of its CE-marked Nu.Q® NETs automated product in Europe in Q1 2025, marking a significant commercial milestone [4] Financial Highlights - Volition reported approximately $0.25 million in revenue for Q1 2025, a 44% increase compared to the same quarter in the previous year [8] - The net cash used in operating activities averaged $1.4 million per month, nearly 50% lower than in Q1 2024 [8] - The company received $4.3 million in funding during Q1 2025, with about $1.8 million from non-dilutive funding [8] - As of March 31, 2025, cash and cash equivalents totaled approximately $2.6 million, down from $3.3 million as of December 31, 2024 [8] - A convertible loan note was finalized post-quarter end, providing $6.25 million in gross proceeds, repayable over 24 months [8] - The goal for 2025 is to achieve cash neutrality, where income matches expenditure on a cash basis [8]

HENDERSON, Nev., April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds, has issued a Shareholder Letter providing a business update.A Message from our Chief Executive Officer2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the human diagnostics market. I am delighted to report we are in confidential di ...

Cameron Reynolds, President and Group Chief Executive Officer, said: "Our focus in 2024 was on generating sufficient clinical data to convince the biggest players in the diagnostic, screening, and liquid biopsy world that our Nu.Q® platform will play a significant role in both the oncology and sepsis markets. I believe this was achieved beyond our expectations: a range of independent studies demonstrating the value of our platform have been completed. We built impressive data rooms in 2024, and 2025 will se ...